国际生殖健康/计划生育杂志
國際生殖健康/計劃生育雜誌
국제생식건강/계화생육잡지
JOURNLA OF INTERNATIONAL REPRODUCTIVE HEALTH/FAMILY PLANNING
2014年
3期
236-238
,共3页
宋瑞芳%苏迎春%杨新红%孙婧
宋瑞芳%囌迎春%楊新紅%孫婧
송서방%소영춘%양신홍%손청
受精,体外%精子注射,细胞质内%胚胎移植%孕酮%妊娠
受精,體外%精子註射,細胞質內%胚胎移植%孕酮%妊娠
수정,체외%정자주사,세포질내%배태이식%잉동%임신
Fertilization in vitro%Sperm injections,intracytoplasmic%Embryo transfer%Progesterone%Pregnancy
目的：探讨注射人绒毛膜促性腺激素（hCG）日之前血清孕酮升高时间对体外受精（IVF）/胞浆内单精子注射（ICSI）-胚胎移植（ET）患者妊娠结局的影响。方法：回顾性分析郑州大学第一附属医院生殖中心2012年6月-2013年6月经IVF/ICSI-ET治疗共2905例患者的临床资料。长方案组根据注射hCG日有无直径≥20 mm卵泡分为A组（2725例）和B组（180例），2组又根据自促排卵日至注射hCG日血清孕酮浓度＞1 ng/mL（1 ng/mL=3.17 nmol/L）时间分为以下3组：孕酮＞1 ng/mL 0 d者分别为A1组（1788例）和B1组（83例）；孕酮≥1 ng/mL 1～2 d者分别为A2组（717例）和B2组（67例）；孕酮≥1 ng/mL时间≥3 d者分别为A3组（220例）和B3组（30例）。比较各组间的妊娠率。结果：A1、A2、A3组妊娠率分别为55.42%、44.21%和41.81%，差异有统计学意义（P＜0.01）。B1、B2、B3组妊娠率分别为48.19%、47.76%和46.66%，差异无统计学意义（P＞0.05）。结论：IVF/ICSI-ET，hCG日存在直径≥20 mm的卵泡时，随着血清孕酮浓度升高（＞1 ng/mL）时间的增加，临床妊娠率会下降。
目的：探討註射人絨毛膜促性腺激素（hCG）日之前血清孕酮升高時間對體外受精（IVF）/胞漿內單精子註射（ICSI）-胚胎移植（ET）患者妊娠結跼的影響。方法：迴顧性分析鄭州大學第一附屬醫院生殖中心2012年6月-2013年6月經IVF/ICSI-ET治療共2905例患者的臨床資料。長方案組根據註射hCG日有無直徑≥20 mm卵泡分為A組（2725例）和B組（180例），2組又根據自促排卵日至註射hCG日血清孕酮濃度＞1 ng/mL（1 ng/mL=3.17 nmol/L）時間分為以下3組：孕酮＞1 ng/mL 0 d者分彆為A1組（1788例）和B1組（83例）；孕酮≥1 ng/mL 1～2 d者分彆為A2組（717例）和B2組（67例）；孕酮≥1 ng/mL時間≥3 d者分彆為A3組（220例）和B3組（30例）。比較各組間的妊娠率。結果：A1、A2、A3組妊娠率分彆為55.42%、44.21%和41.81%，差異有統計學意義（P＜0.01）。B1、B2、B3組妊娠率分彆為48.19%、47.76%和46.66%，差異無統計學意義（P＞0.05）。結論：IVF/ICSI-ET，hCG日存在直徑≥20 mm的卵泡時，隨著血清孕酮濃度升高（＞1 ng/mL）時間的增加，臨床妊娠率會下降。
목적：탐토주사인융모막촉성선격소（hCG）일지전혈청잉동승고시간대체외수정（IVF）/포장내단정자주사（ICSI）-배태이식（ET）환자임신결국적영향。방법：회고성분석정주대학제일부속의원생식중심2012년6월-2013년6월경IVF/ICSI-ET치료공2905례환자적림상자료。장방안조근거주사hCG일유무직경≥20 mm란포분위A조（2725례）화B조（180례），2조우근거자촉배란일지주사hCG일혈청잉동농도＞1 ng/mL（1 ng/mL=3.17 nmol/L）시간분위이하3조：잉동＞1 ng/mL 0 d자분별위A1조（1788례）화B1조（83례）；잉동≥1 ng/mL 1～2 d자분별위A2조（717례）화B2조（67례）；잉동≥1 ng/mL시간≥3 d자분별위A3조（220례）화B3조（30례）。비교각조간적임신솔。결과：A1、A2、A3조임신솔분별위55.42%、44.21%화41.81%，차이유통계학의의（P＜0.01）。B1、B2、B3조임신솔분별위48.19%、47.76%화46.66%，차이무통계학의의（P＞0.05）。결론：IVF/ICSI-ET，hCG일존재직경≥20 mm적란포시，수착혈청잉동농도승고（＞1 ng/mL）시간적증가，림상임신솔회하강。
Objective:To explore the effect of days of the elevated serum progesterone before hCG administration on the outcomes of IVF/ICSI-ET treatment. Methods:2 905 cases of IVF/ICSI -ET treatment, from June 2012 to June 2013, were divided into two groups according to whether finding the follicle (s) of diameter≥20 mm (Group A 2 725 cases, and Group B 180 cases) on the hCG day. Two groups were respectively divided into 3 subgroups according to days of the elevated level of progesterone (>1 ng/mL). Group A1 (1 788 cases) and B1 (83 cases) had 0 day of the elevated level of progesterone. Group A2 (717 cases) and B2 (67 cases) had 1-2 days of the elevated level of progesterone. Groups A3 (220 cases) and B3 (30 cases) had ≥3 days of the elevated level of progesterone. The clinical pregnancy rates of groups were meticulously compared. Results:There was significant difference in the clinical pregnancy rates among the Group A1 (55.42%), A2 (44.21%) and A3 (41.81%, P<0.01). Interestingly, there was no significant difference in those rates among the Group B1 (48.19%), B2 (47.76%) and B3 (46.66%, P>0.05). Conclusions:The clinical pregnancy rate could decrease following days of the elevated level of serum progesterone (>1 ng/mL) in those IVF/ICSI-ET patients with the follicle(s) of diameter≥20 mm on the hCG day.
